Loading clinical trials...

Avocado and Postprandial Responses | Clinical Trials | Clareo Health

RECRUITINGNA

Avocado and Postprandial Responses

Acute Avocado Consumption on Postprandial Glycemic and Appetite/Satiety Responses

NCT06818032•University of Vermont Medical Center

Summary

The purpose of this study is to see how adding avocado to a breakfast meal affects blood sugar control and signals of hunger and fullness after eating. The investigators will test the effects of 3 breakfast meals on blood sugar control and signals of hunger and fullness after eating: 1. Whole-wheat bread and strawberry jam 2. Whole-wheat bread, strawberry jam, and avocado 3. Whole-wheat bread and strawberry jam (meal enriched with fat and fiber to mimic that of an avocado) Participants will undergo 3 test periods, each separated by a week. Each test period consists of one day with set meals that the investigators will provide (breakfast, lunch, and dinner), and then the next morning, participants will eat a breakfast meal and have blood drawn several times over 4 hours.

Eligibility

Age

21 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Biological sex males or females
•Age 21 to 65 years
•BMI between 18.5 and 34.9 kg/m2

Exclusion Criteria

•Actively pregnant or lactating women
•Diagnosis of prediabetes or diabetes (fasting glucose \>100 mg/dL)
•Current diagnosis of uncontrolled hypertension (systolic BP: \>160 mmHg, diastolic BP: \>95 mmHg), may receive treatment for hypertension as long as on a stable regimen for the previous one month
•Current diagnosis of uncontrolled hyperlipidemia (fasting total blood cholesterol \>200 mg/dL, fasting triglycerides \>200 mg/dL), may receive treatment for hyperlipidemia as long as on a stable regimen for the previous one month
•Presence of kidney disease, liver disease, hyperthyroidism, untreated or unstable hypothyroidism, certain cancers, gastrointestinal disease, pancreatic disease, other chronic metabolic diseases or malabsorption syndromes, HIV, or inflammatory conditions (such as arthritis, asthma, Crohn's disease, inflammatory bowel disease, gout, Lupus)
•History of bariatric or certain other surgeries related to weight control
•Any medication used to lower blood glucose/antidiabetic medications \[including, but not limited to metformin, sulfonylureas, glucagon-like peptide-1 (GLP-1) analogues, sodium-glucose cotransporter-2 (SGL2) inhibitors, thiazolidinediones, dipeptidyl peptidase (DPP)-IV inhibitors\] as well as medications affecting weight, appetite/hunger or gut motility.
•Smoking or use of other tobacco products (during 6 months prior to the start of the study)
•Antibiotic use during the intervention or for 3 weeks prior to any treatment period
•History of eating disorders or other significant food preferences that would interfere with the diet intervention (e.g., vegan lifestyle, very low-fat diets, high-protein diets)
+6 more criteria

Locations (1)

Clinical Research Center, University of Vermont Medical Center

Burlington, Vermont, United States

Key Dates

Start Date

March 1, 2025

Primary Completion Date

February 1, 2026

Completion Date

June 1, 2026

Last Updated

March 28, 2025

Enrollment

ESTIMATED participants

Conditions

HealthyHealthy VolunteerHealthy VolunteersHealthy AdultHealthy Male and Female SubjectsHealthy SubjectsHealthy Volunteers OnlyHealthy Non-smokers

Interventions

Negative control

OTHER

Avocado

OTHER

Fat and fiber addition

OTHER

Contacts

Clinical Research Project Manager

CONTACT

802-656-8827 foodstudy@uvm.edu

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

NCT06290258

Autism Spectrum DisorderGastrointestinal Diseases+1 more

View study

RECRUITINGNA

A New Portable Device for Non-invasive Ventilatory Support

NCT06716502

HealthyRespiratory Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 28, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Avocado and Postprandial Responses

Inclusion Criteria

Exclusion Criteria

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

A New Portable Device for Non-invasive Ventilatory Support

Collection of Data and Samples From Healthy Donors for Use in Translational Research

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Turkish Validity and Reliability Study of PRevention of Toxic Chemicals in the Environment for Children Tool

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases